917251-86-6

Basic information

• Product Name: 8-Bromo-3-(trifluoromethyl)quinoline
• Synonyms: 8-Bromo-3-(trifluoromethyl)quinoline;Quinoline, 8-broMo-3-(trifluoroMethyl)-
• CAS NO: 917251-86-6
• Molecular Formula: C10H5BrF3N
• Molecular Weight: 276.0526096
• Mol File: 917251-86-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 301.343 °C at 760 mmHg
• Flash Point: 136.048 °C
• Appearance: /
• Density: 1.658 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 8-Bromo-3-(trifluoromethyl)quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromo-3-(trifluoromethyl)quinoline(917251-86-6)
• EPA Substance Registry System: 8-Bromo-3-(trifluoromethyl)quinoline(917251-86-6)

Safety Data

• Hazardous Substances Data: 917251-86-6(Hazardous Substances Data)

Usage

General Description

8-Bromo-3-(trifluoromethyl)quinoline is a chemical compound with the molecular formula C11H6BrF3N. It is a quinoline derivative that contains a bromine atom and a trifluoromethyl group attached to the quinoline ring. 8-Bromo-3-(trifluoromethyl)quinoline is commonly used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and bioactive molecules due to its unique structure and properties. The trifluoromethyl group can enhance the bioavailability and metabolic stability of drug molecules, making it a valuable chemical in medicinal chemistry. Additionally, the bromine atom can serve as a versatile functional group for further chemical modifications, making 8-Bromo-3-(trifluoromethyl)quinoline a versatile and valuable compound in chemical and pharmaceutical research.

InChI:InChI=1/C10H5BrF3N/c11-8-3-1-2-6-4-7(10(12,13)14)5-15-9(6)8/h1-5H

Upstream product

• 25199-76-2 3-(trifluoromethyl)quinoline 
• 917251-85-5 8-bromo-3-iodoquinoline 
• 10112-11-5 (trifluoromethyl)silane 
• 81290-20-2 (trifluoromethyl)trimethylsilane 

Relevant articles and documents

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists

As part of an effort to identify 5-HT1A antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT 1A antagonist/SSRI program. This quinolyl-piperazinyl piperidine analogue displayed potent, selective 5-HT1A antagonism but suffered from poor oxidative metabolic stability, resulting in low exposure following oral administration. SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance. Further changes to the scaffold (e.g., 10r) resulted in a loss in potency. Compound 10b displayed cognitive enhancing effects in a number of animal models of learning and memory, enhanced the antidepressant-like effects of the SSRI fluoxetine, and reversed the sexual dysfunction induced by chronic fluoxetine treatment.

Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor

The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.